Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
liposomal irinotecan + fluorouracil + leucovorin + lenvatinib + PD-1 inhibitor
- Development stage
- Unknown
- Lead developer
- Tianjin Medical University Cancer Institute and Hospital
- Modality
- Small Molecules, Liposomes → Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Hepatic Arterial Infusion, Oral, Intravenous
01
Overview
This combination therapy is an experimental first-line treatment regimen for advanced, unresectable, or metastatic intrahepatic cholangiocarcinoma (ICC). It utilizes Hepatic Arterial Infusion Chemotherapy (HAIC) to deliver a modified FOLFIRI-like regimen consisting of liposomal irinotecan, 5-fluorouracil, and leucovorin directly to the liver. This localized delivery is combined with the systemic administration of lenvatinib, an oral multikinase inhibitor, and an intravenous programmed cell death protein 1 (PD-1) inhibitor. The rationale behind this multi-modal approach is to leverage the local cytotoxic effects of HAIC, the anti-angiogenic and oncogenic signaling inhibition of lenvatinib, and the immune-potentiating effects of checkpoint inhibition to improve objective response rates and survival in patients with biliary tract cancers.
- Other names
- HAIC (liposomal irinotecan, 5-fluorouracil, leucovorin) + lenvatinib + PD-1 inhibitor
02
Targets
FGFR4 (Fibroblast growth factor receptor 4)PDGFRA (Platelet-derived growth factor receptor alpha)TS (Thymidylate synthase)KIT (c-KIT proto-oncogene receptor tyrosine kinase)FGFR3 (Fibroblast growth factor receptor 3)TOP1 (DNA Topoisomerase I)VEGFR3 (Vascular endothelial growth factor receptor 3)VEGFR-1 (Vascular endothelial growth factor receptor 1)VEGFR2 (Vascular endothelial growth factor receptor 2)FGFR1 (Fibroblast growth factor receptor 1)RET (Rearranged during transfection receptor tyrosine kinase)FGFR2 (Keratinocyte growth factor receptor)PDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on liposomal irinotecan + fluorouracil + leucovorin + lenvatinib + PD-1 inhibitor.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on liposomal irinotecan + fluorouracil + leucovorin + lenvatinib + PD-1 inhibitor.